Repros Therapeutics Inc. (RPRX) announced Monday morning that it now plans to provide clinical results from the first pivotal study, ZA-301, of Androxal, in the treatment of secondary hypogonadism in Q3 2013 instead of Q2 2013. The company stated that during the ongoing review of the data it was determined that one site's patient population was markedly different from the other 16 sites from the standpoint of baseline sperm counts.
Repros Therapeutics sharply declined until mid-morning Monday and slipped further going into the close. The stock finished down by 7.50 at $11.11 on the highest volume of the year. Repros sank to a 5-month low and dropped below both its 50 and 200-day moving averages.
by RTT Staff Writer
For comments and feedback: email@example.com